|
|
||||||||
1 National Reference Centre for Mycobacteriology, National Microbiology Laboratory, Health Canada, Winnipeg, Manitoba, Canada R3E 3R2
2 Laboratoire de santé publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada
3 Royal University Hospital, Saskatoon, Saskatchewan, Canada
4 Division of Respiratory Medicine, Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
5 Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
Correspondence
C. Y. Turenne
cturenne{at}hc-sc.gc.ca
| ABSTRACT |
|---|
|
|
|---|
Published online ahead of print on 31 October 2003 as DOI 10.1099/ijs.0.02739-0.
The GenBank/EMBL/DDBJ accession numbers for the 16S rRNA gene, ITS1 and partial hsp65 gene sequences of strains 00-250T and MB54784 are AY208856AY208859.
Details of the strains analysed in this study, photos of colonies and an ITS1 alignment are available as supplementary material in IJSEM Online.
| INTRODUCTION |
|---|
|
|
|---|
Strains that are not M. avium or Mycobacterium intracellulare but that are MAC DNA probe positive, often referred to as MAIX isolates or X strains, have been described previously (Cregan et al., 1992
; Smole et al., 2002
; Soini et al., 1994
, 1996
; Tortoli et al., 1997
; Viljanen et al., 1993
). Sequence-based evaluations of the 32 kDa protein (Soini et al., 1994
, 1996
), internal transcribed spacer (ITS1) region (Frothingham & Wilson, 1993
) and hsp65 gene (Smole et al., 2002
) have suggested that some MAIX strains represent novel species within the complex. We present a clinically significant case of NTM pulmonary infection caused by a novel species of mycobacteria that is MAC AccuProbe positive, but presents with a unique combination of genotypic and phenotypic characteristics. Additional strains with identical characteristics were identified from other specimens and have been included in this study.
| METHODS |
|---|
|
|
|---|
Re-evaluation by a respiratory specialist, including chest X-ray and pulmonary function tests, in August 2000 revealed new left upper lobe cavitary lesions. Multiple sputum specimens were positive for AFB (4+), identified by nucleic acid probe as MAC. The patient deteriorated rapidly and was admitted to hospital presenting with a new left pleural effusion and left lower lobe pneumonia. She did not respond to 5 days of intravenous piperacillin/tazobactam and was then placed on a three-drug regimen of ciprofloxacin, azithromycin and amikacin, to which she responded clinically within 48 h. After 5 weeks on this regimen, clinical response was marked and her pleural effusion had resolved, although her sputum samples continued to reveal AFB (1+) with positive culture for M. avium based on nucleic acid probes. After 8 weeks of therapy, rifabutin was substituted for amikacin. Compliance with this new regimen was approximately 60 %, due to gastrointestinal intolerance, and rifabutin was discontinued after 4 weeks due to a fourfold rise in her hepatic transaminases. After 5 months on the two-drug regimen (ciprofloxacin, azithromycin), sputum was negative for AFB by stain and culture and she was clinically well with stable X-rays. After a treatment ration of 9 months, sputum cultures remain negative for AFB.
Concurrently, one of the strains isolated in summer 2000, strain 00-250T, was submitted to the National Reference Centre for Mycobacteriology for MAC susceptibility testing, where the unusual morphology of the organism prompted 16S rRNA gene sequence identification. It was determined that the organism was distinct from any established mycobacterium species and was more closely related to Mycobacterium interjectum on the basis of 16S rDNA analysis. Two other isolates were obtained from the patient and were submitted for 16S rDNA sequencing identification. One was from sputum (strain 01-244), which was isolated earlier, in July 1999, and identified by biochemical tests as M. gordonae. The other strain was from thoracenthesis fluid (strain 00-308, isolated September 2000). It was determined that the same organism was isolated in each case.
Strains.
Three strains from the patient were made available for this study. One of these, strain 00-250T, was sent for HPLC analysis to the Laboratoire de Santé Publique du Québec and showed a similar pattern to several isolates identified by HPLC as M. interjectum-like from various regions of Québec over the last decade. Sequencing of the 16S rDNA indicated that a great proportion of these were identical to the strains isolated from the case discussed above and were included in this study to provide a better representation of the susceptibility and phenotypic and genotypic characteristics of this novel species. Strain isolation and patient data of the 16 strains (13 from Québec and three from the case report) are available as a supplementary table in IJSEM Online.
Phenotypic properties.
A standard series of biochemical tests, growth temperatures and morphological examination for mycobacteriology were performed as described previously (Kent & Kubica, 1985
), as listed in Table 1
.
|
DNA probe.
AccuProbe assays (Gen-Probe) for MAC were performed using colonies from pure culture of the 16 isolates in this study.
HPLC.
HPLC by UV detection was performed according to the standard methodology (Butler et al., 1996
).
Sequencing of the 16S rDNA and ITS1 region.
A loopful of organism from pure culture was suspended in sterile distilled water, boiled for 10 min and then subjected to mechanical lysis using a Mini Bead-Beater (Biospec Products). Lysates were then centrifuged for 2 min at 12 000 g and the supernatant was used for PCR. Amplification of the 16S rRNA gene (Rogall et al., 1990
; Turenne et al., 2001
) and the ITS1 region (Harmsen et al., 2002
; Turenne et al., 2002
) was performed as described previously and PCR products were sequenced directly using forward and reverse primers and loaded on an ABI PRISM 310 Genetic Analyzer capillary sequencer (Applied Biosystems). Sequence editing and phylogenetic analyses by CLUSTAL V (neighbour-joining method) were performed using the SEQMAN and MEGALIGN components of lasergene 5 (DNASTAR).
Sequencing and PCR-restriction enzyme analysis (PRA) of the hsp65 gene.
A 441-bp fragment of the hsp65 gene was amplified from the DNA lysates prepared above using the protocol described previously (Telenti et al., 1993
). The resulting PCR product was sequenced using the forward and reverse PCR primers TB11 and TB12. Computer-generated PRA profiles of 441-bp sequences with enzymes HaeIII and BstEII were determined using MapDraw (DNASTAR).
| RESULTS AND DISCUSSION |
|---|
|
|
|---|
Susceptibility testing
According to current NCCLS guidelines for susceptibility testing of MAC and proposed resistance breakpoints for Mycobacterium kansasii (NCCLS, 2000
), all isolates were resistant to isoniazid and sensitive to rifampicin, rifabutin, streptomycin, clarithromycin, amikacin, ciprofloxacin and sulfamethoxazole (Table 2
). For ethambutol, 86 % of isolates were susceptible using a resistance breakpoint of 10 µg ml1. If proposed breakpoints for linezolid and rapidly growing mycobacteria are employed (Wallace et al., 2001
), all isolates were susceptible to this antimicrobial. Low MIC values for moxifloxacin and levofloxacin may indicate in vitro susceptibility to these flouroquinolones.
|
|
|
|
Sequencing and PRA of the hsp65 gene
Sequences of a 441-bp region of hsp65 revealed four distinct sequevars, Msk1, Msk2, Msk3 and Msk4 (Supplementary Table, Fig. 3b
), most with 1 or 2 base variations from each other. The exception was strain MB54784 from Québec, or sequevar Msk4, which differed by 20 bases from Msk1. Msk1 was the most prevalent, followed by sequevar Msk2, which differed from Msk1 by 1 base, at position 411 of the 441-bp fragment. Sequevar Msk3, represented by strain MB13405 alone, differed from Msk1 by 2 bases, at positions 264 and 411 of the 441-bp fragment. The closest established species as determined by 16S rDNA analysis were also sequenced for the partial hsp65 gene and compared with the clinical isolates (Fig. 3b
). Sequevars Msk1, Msk2 and Msk3 are most closely related to M. interjectum ATCC 51457T, differing from Msk1 by 7 bases. BLAST analysis of the partial hsp65 sequence was performed with Msk1 and Msk4, using positions 46405 of the 441-bp fragment to obtain the most accurate top score with mycobacterial hsp65 sequences in the public database, most being either 401 or 360 bp in length. BLAST results of Msk1 revealed a top score with M. interjectum (AJ307632), with seven mismatches, corresponding to that determined with our in-house sequence of the type strain. BLAST results of strain MB54784 (Msk4) revealed a top score and eight mismatches with M. gordonae SN 601 (AF434735), which differs from M. gordonae ATCC 14470T (AF434734) by 30 bases.
Computerized restriction maps of the 441-bp hsp65 fragment as determined by MAPDRAW (LaserGene) revealed the presence of fragments of 231 and 210 bp with BstEII and 127 and 145 bp with HaeIII digestion in sequevars Msk1, Msk2 and Msk3 (Table 3
). Fragments smaller than 50 bp were not taken into account. This pattern corresponds exactly with that of M. interjectum (da Silva Rocha et al., 2002
), M. avium III (Leao et al., 1999
) and MAC isolate Mav v3 (Smole et al., 2002
). Sequevar Msk4, however, presents a PRA pattern of 231, 131 and 79 bp fragments with BstEII and 127 and 94 bp fragments with HaeIII, which does not correspond to published PRA patterns derived from sequence analysis (Brunello et al., 2001
).
|
Some studies based on PRA of the partial hsp65 gene have shown isolates with an identical profile to that determined for our sequevars Msk1, Msk2 and Msk3. We obtained sequence data from a study that included hsp65 sequence data (360 bp) for three strains that had an identical PRA profile to that of our strains (Smole et al., 2002
) and compared these with our sequences. These three strains, M. avium v3 920A-120 (AF241202), M. avium v3 121B-60.1 (AF354282) and M. avium v3 953A-145 (AF354283), were found to differ from our sequevar Msk1 by 15, 15 and 19 mismatches, respectively. Another study describes isolates identified as M. avium III, with an identical PRA pattern, that hybridized exclusively with M. avium-specific probes and not M. intracellulare (Leao et al., 1999
). It is unclear whether an MAC probe was done, and 16S rDNA data were not included. The proportion of M. avium III strains from human isolates was 6·5 % (out of 107 isolates). A 441-bp hsp65 sequence available for strain M. avium III (AF126033) was found to be identical to that of M. avium v3 953A-145 and therefore distinct from our sequences, with 96·4 % sequence identity or 16 mismatches in the 441-bp fragment from Msk1.
Another study suggested that the M. interjectum PRA pattern, which we determined to be identical to that of our strains, is also similar to M. simiae II-3 (Taylor et al., 1997
), M. intracellulare 3 and M. intermedium I (da Silva Rocha et al., 2002
). Our computer-generated analysis of M. intermedium shows an additional 129 bp fragment in the HaeIII digest, which would be indistinguishable from the 127 bp fragment using gel electrophoresis. Further PRA comparisons with available data from PRA profiles alone were difficult due to subjectivity and procedure variations, particularly with gel concentrations (Brunello et al., 2001
; Strässle et al., 2001
), where discrepancies between sequence-based PRA pattern determination and published data from gel electrophoresis (Telenti et al., 1993
) can reach up to 14 bases. While PRA is a common method of choice due to its ease and rapidity, the reliability of PRA pattern determination is somewhat limited and may occasionally result in misidentification (Strässle et al., 2001
). Finally, even within what are determined to be isolates of the MAC, various PRA patterns are observed, some of which are similar to those of other NTM species.
We recognized a similarity between our isolates and strain FI-16795 (Tortoli et al., 1997
) due its scotochromogenicity, MAC AccuProbe positivity and similar HPLC profile. This isolate was subsequently identified as M. palustre and was evaluated, along with other isolates of M. palustre, in the publication describing the species (Torkko et al., 2002
).
Clinical significance
The patient described in this case history presented with a clinical history of bronchiectasis of unknown aetiology, documented first in around 1990 by CT. The absence of an alternative pathogenic agent supports the potential clinical relevance of this novel species. It is likely that this patient developed bronchiectasis from recurrent infections or an underlying lung disease, which rendered her susceptible to an atypical mycobacteriosis caused by this organism. It is well known that most NTM are not considered pathogenic; however, correct species determination is important in order to make appropriate treatment decisions. The limitations of biochemical testing were demonstrated in this case, as the NTM recovered initially from the patient was identified as M. gordonae and considered not to be responsible for the disease, even though the recovery of AFB from three sputum samples, according to the American Thoracic Society criteria (Wallace et al., 1997
), would suggest a diagnosis of an NTM infection. Perhaps earlier intervention, in 1999, would have prevented further lung damage. All other isolates in our study were recovered from respiratory specimens, and no extensive clinical history is available. However, in two instances, the same isolate was recovered twice from the same patient in two different years. Also, one patient tested repeatedly from 1993 to 1996 yielded seven isolates, and the organism's pathogenicity in this case is therefore considered highly probable (Wallace et al., 1997
).
Differentiation of Mycobacterium saskatchewanense sp. nov. from other slowly growing NTM
The group of unique strains evaluated in this study represent a species that, depending on the methodology used for identification, mimics various established species of mycobacteria. Without sequence-based identification, M. saskatchewanense sp. nov. may be difficult to recognize. Although the MAC AccuProbe is positive for these isolates, colony morphology and pigmentation are very distinct from M. avium or M. intracellulare. Additionally, the inability to grow at 42 °C, a positive Tween 80 hydrolysis test and negative pyrazinamidase test differentiate this species from M. avium and M. intracellulare. M. saskatchewanense can also be differentiated from another recently described AccuProbe positive species, M. palustre, by its inability to grow at 42 °C and negative results for urease, pyrazinamidase and acid phosphatase. Biochemically, M. saskatchewanense most closely resembles M. gordonae, and phenotypic differentiation is subtle. This redundancy in biochemical profiles is not surprising, given the large number of mycobacteria currently established (>100). The HPLC pattern of the strains evaluated in this study is distinct from the other late-emerging single-cluster peak patterns, with the exception of M. palustre, mainly in the relative heights of corresponding late peaks. The HPLC pattern is also very similar to some published profiles of strains identified as M. interjectum; however, it is distinct from the pattern observed in the type strain of M. interjectum. Despite sequence mismatches in the hsp65 gene, PRA analysis of M. saskatchewanense, M. interjectum, selected strains designated MAC and M. intermedium using enzymes BstEII and HaeIII revealed an identical pattern. While the type strain of M. intermedium is non-chromogenic, the morphologies of M. interjectum and M. saskatchewanense are similar. M. saskatchewanense can be differentiated from M. interjectum, MAC, M. gordonae, M. kubicae, M. palustre and other mycobacteria by its 16S rRNA gene, ITS1 and hsp65 gene sequences, confirming the isolate as representing a novel species.
Description of Mycobacterium saskatchewanense sp. nov.
Mycobacterium saskatchewanense (sas.kat.che.wa.nen'se. N.L. neut. adj. saskatchewanense pertaining to Saskatchewan).
Cells are acidalcohol-fast, long, beaded rods. Grows at 2537 °C, but not at 42 °C. The organism shows a bright yellow pigment under both light and dark conditions. Strains with an identical 16S rRNA gene sequence to that of 00-250T are MAC AccuProbe positive. Negative for acid phosphatase, arylsulfatase,
-glucosidase, niacin, nitrate reductase, pyrazinamidase and urease and does not grow on 5 % NaCl. Some strains show a thin film of growth on MacConkey agar without crystal violet. Other variable test results include semi-quantitative catalase and tellurite reduction. Most isolates are strongly positive for Tween 80 hydrolysis and all isolates have heat-stable catalase activity. Mycolic acids of the cell wall produce a single-cluster pattern by HPLC, typical of M. kubicae, M. palustre and some documented clinical strains of M. interjectum. Sequencing of the 16S rRNA, hsp65 gene and ITS1 region reveals unique data that are crucial in the differentiation of this species from selected NTM species. Isolates are susceptible in vitro to amikacin, clarithromycin, ciprofloxacin, linezolid, levofloxacin, moxifloxacin, rifabutin, rifampicin, streptomycin and sulfamethoxazole and are resistant to isoniazid. Eighty-six per cent of isolates are susceptible to ethambutol, with a resistance breakpoint of 10 µg ml1. Strains have been isolated from human respiratory samples and were proven to be clinically significant in our case study. Strain MB54784 may constitute a distinct species, since it shows significant hsp65 and ITS1 sequence variation; however, due to phenotypic and 16S rDNA similarities, this is difficult to establish at this time.
The type strain is strain 00-250T (=ATCC BAA-544T=DSM 44616T=CIP 108114T), which was isolated from the sputum of a patient with bronchiectasis.
| ACKNOWLEDGEMENTS |
|---|
| REFERENCES |
|---|
|
|
|---|
Brunello, F., Ligozzi, M., Cristelli, E., Bonora, S., Tortoli, E. & Fontana, R. (2001). Identification of 54 mycobacterial species by PCR-restriction fragment length polymorphism analysis of the hsp65 gene. J Clin Microbiol 39, 27992806.
Butler, W. R. & Guthertz, L. S. (2001). Mycolic acid analysis by high-performance liquid chromatography for identification of Mycobacterium species. Clin Microbiol Rev 14, 704726.
Butler, W. R., Floyd, M. M., Silcox, V. A. & 9 other authors (1996). Standardized Method for HPLC Identification of Mycobacteria. Atlanta: US Dept of Health and Human Services, Centers for Disease Control and Prevention.
Cregan, P., Yajko, D. M., Ng, V. L., Gonzalez, P. C., Nassos, P. S., Sanders, C. A. & Hadley, W. K. (1992). Use of DNA probes to detect Mycobacterium intracellulare and "X" mycobacteria among clinical isolates of Mycobacterium avium complex. J Infect Dis 166, 191194.[Medline]
da Silva Rocha, A., Werneck Barreto, A. M., Dias Campos, C. E., Villas-Boas da Silva, M., Fonseca, L., Saad, M. H., Degrave, W. M. & Suffys, P. N. (2002). Novel allelic variants of mycobacteria isolated in Brazil as determined by PCR-restriction enzyme analysis of hsp65. J Clin Microbiol 40, 41914196.
Frothingham, R. & Wilson, K. H. (1993). Sequence-based differentiation of strains in the Mycobacterium avium complex. J Bacteriol 175, 28182825.
Harmsen, D., Rothganger, J., Frosch, M. & Albert, J. (2002). RIDOM: ribosomal differentiation of medical micro-organisms database. Nucleic Acids Res 30, 416417.
Heifets, L., Lindholm-Levy, P., Libonati, J. P., Hooper, N., Laszlo, A., Cynamon, M. & Siddiqi, S. (1993). Radiometric Broth Macrodilution Method for the Determination of Minimal Inhibitory Concentrations (MIC) with Mycobacterium avium Complex Isolates. Denver: National Jewish Center for Immunology and Respiratory Medicine.
Kent, P. T. & Kubica, G. P. (1985). Public Health Mycobacteriology: a Guide for the Level III Laboratory. Atlanta: US Department of Health and Human Services, Centers for Disease Control.
Leao, S. C., Briones, M. R., Sircili, M. P., Balian, S. C., Mores, N. & Ferreira-Neto, J. S. (1999). Identification of two novel Mycobacterium avium allelic variants in pig and human isolates from Brazil by PCR-restriction enzyme analysis. J Clin Microbiol 37, 25922597.
Lumb, R., Goodwin, A., Ratcliff, R., Stapledon, R., Holland, A. & Bastian, I. (1997). Phenotypic and molecular characterization of three clinical isolates of Mycobacterium interjectum. J Clin Microbiol 35, 27822785.[Abstract]
NCCLS (2000). Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes. Tentative standard M24-T2, 2nd edn. Wayne, PA: National Committee for Laboratory Standards.
Rogall, T., Wolters, J., Flohr, T. & Böttger, E. C. (1990). Towards a phylogeny and definition of species at the molecular level within the genus Mycobacterium. Int J Syst Bacteriol 40, 323330.[CrossRef][Medline]
Shinnick, T. M. (1987). The 65-kilodalton antigen of Mycobacterium tuberculosis. J Bacteriol 169, 10801088.
Smole, S. C., McAleese, F., Ngampasutadol, J., von Reyn, C. F. & Arbeit, R. D. (2002). Clinical and epidemiological correlates of genotypes within the Mycobacterium avium complex defined by restriction and sequence analysis of hsp65. J Clin Microbiol 40, 33743380.
Soini, H., Bottger, E. C. & Viljanen, M. K. (1994). Identification of mycobacteria by PCR-based sequence determination of the 32-kilodalton protein gene. J Clin Microbiol 32, 29442947.
Soini, H., Eerola, E. & Viljanen, M. K. (1996). Genetic diversity among Mycobacterium avium complex AccuProbe-positive isolates. J Clin Microbiol 34, 5557.[Abstract]
Springer, B., Kirschner, P., Rost-Meyer, G., Schroder, K. H., Kroppenstedt, R. M. & Bottger, E. C. (1993). Mycobacterium interjectum, a new species isolated from a patient with chronic lymphadenitis. J Clin Microbiol 31, 30833089.
Springer, B., Stockman, L., Teschner, K., Roberts, G. D. & Bottger, E. C. (1996). Two-laboratory collaborative study on identification of mycobacteria: molecular versus phenotypic methods. J Clin Microbiol 34, 296303.[Abstract]
Strässle, A., Truong, M. & Pfyffer, G. E. (2001). Identification of non-tuberculous mycobacteria by PCR/restriction enzyme analysis of the 65-kDa heat shock protein gene: trick or treat? In Abstracts of the 102nd General Meeting of the American Society for Microbiology, abstract U11. Washington, DC: American Society for Microbiology.
Taylor, T. B., Patterson, C., Hale, Y. & Safranek, W. W. (1997). Routine use of PCR-restriction fragment length polymorphism analysis for identification of mycobacteria growing in liquid media. J Clin Microbiol 35, 7985.[Abstract]
Telenti, A., Marchesi, F., Balz, M., Bally, F., Bottger, E. C. & Bodmer, T. (1993). Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol 31, 175178.
Torkko, P., Suomalainen, S., Iivanainen, E., Tortoli, E., Suutari, M., Seppänen, J., Paulin, L. & Katila, M.-L. (2002). Mycobacterium palustre sp. nov., a potentially pathogenic, slowly growing mycobacterium isolated from clinical and veterinary specimens and from Finnish stream waters. Int J Syst Evol Microbiol 52, 15191525.[Abstract]
Tortoli, E., Bartoloni, A., Burrini, C., Colombrita, D., Mantella, A., Pinsi, G., Simonetti, M. T., Swierczynski, G. & Bottger, E. C. (1996). Characterization of an isolate of the newly described species Mycobacterium interjectum. Zentbl Bakteriol 283, 286294.
Tortoli, E., Piersimoni, C., Kirschner, P. & 10 other authors (1997). Characterization of mycobacterial isolates phylogenetically related to, but different from Mycobacterium simiae. J Clin Microbiol 35, 697702.[Abstract]
Turenne, C. Y., Tschetter, L., Wolfe, J. & Kabani, A. (2001). Necessity of quality-controlled 16S rRNA gene sequence databases: identifying nontuberculous Mycobacterium species. J Clin Microbiol 39, 36373648.
Turenne, C., Chedore, P., Wolfe, J., Jamieson, F., Broukhanski, G., May, K. & Kabani, A. (2002). Mycobacterium lacus sp. nov., a novel slowly growing, non-chromogenic clinical isolate. Int J Syst Evol Microbiol 52, 21352140.[Abstract]
Viljanen, M. K., Olkkonen, L. & Katila, M. L. (1993). Conventional identification characteristics, mycolate and fatty acid composition, and clinical significance of MAIX AccuProbe-positive isolates of Mycobacterium avium complex. J Clin Microbiol 31, 13761378.
Wallace, R. J., Jr, Nash, D. R., Steele, L. C. & Steingrube, V. (1986). Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J Clin Microbiol 24, 976981.
Wallace, R. J., Jr, Glassroth, J., Griffith, D. E., Olivier, K. N., Cook, J. L. & Gordin, F. (1997). Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Official statement of the American Thoracic Society. Am J Respir Crit Care Med 156, S1S25.
Wallace, R. J., Jr, Brown-Elliott, B. A., Ward, S. C., Crist, C. J., Mann, L. B. & Wilson, R. W. (2001). Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 45, 764767.
This article has been cited by other articles:
![]() |
O. Esparcia, F. Navarro, M. Quer, and P. Coll Lymphadenopathy Caused by Mycobacterium colombiense J. Clin. Microbiol., May 1, 2008; 46(5): 1885 - 1887. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Y. Turenne, R. Wallace Jr., and M. A. Behr Mycobacterium avium in the Postgenomic Era Clin. Microbiol. Rev., April 1, 2007; 20(2): 205 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pignone, K. M. Greth, J. Cooper, D. Emerson, and J. Tang Identification of Mycobacteria by Matrix-Assisted Laser Desorption Ionization-Time-of-Flight Mass Spectrometry. J. Clin. Microbiol., June 1, 2006; 44(6): 1963 - 1970. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Drancourt and D. Raoult Sequence-Based Identification of New Bacteria: a Proposition for Creation of an Orphan Bacterium Repository J. Clin. Microbiol., September 1, 2005; 43(9): 4311 - 4315. [Full Text] [PDF] |
||||
![]() |
J. L. Cloud, K. C. Carroll, S. Cohen, C. M. Anderson, and G. L. Woods Interpretive Criteria for Use of AccuProbe for Identification of Mycobacterium avium Complex Directly from 7H9 Broth Cultures J. Clin. Microbiol., July 1, 2005; 43(7): 3474 - 3478. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Tortoli, L. Rindi, K. S. Goh, M. L. Katila, A. Mariottini, R. Mattei, G. Mazzarelli, S. Suomalainen, P. Torkko, and N. Rastogi Mycobacterium florentinum sp. nov., isolated from humans Int J Syst Evol Microbiol, May 1, 2005; 55(3): 1101 - 1106. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |